BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.45, Yahoo Finance reports.
BriaCell Therapeutics Trading Down 2.1 %
Shares of BriaCell Therapeutics stock opened at $0.82 on Wednesday. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97. The stock has a market capitalization of $14.90 million, a price-to-earnings ratio of -0.67 and a beta of 1.34. The business’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $1.15.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a report on Thursday, October 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 ETFs With Low Fees and Market-Beating Returns
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
